From early research to quality control, maintaining analytical continuity is no easy task. Could a single sequencing workflow help simplify analytical assessment?
One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the science behind FcRn and how researchers measure its function.
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How is the field adapting to meet these new demands?
What if the vast amounts of data generated by molecular dynamics simulations could be routinely shared and reused? A new €10 million European initiative aims to do just that, helping researchers gain a deeper understanding of protein behaviour and drug-target interactions.
A peptide vaccine targeting PCSK9 has demonstrated sustained antibody responses and reductions in LDL cholesterol and atherosclerotic plaque formation in animal models, offering a potential long-term alternative to current lipid-lowering therapies.
Scientists at MD Anderson Cancer Center have revealed how ATRX mutations restructure chromatin and activate oncogenic developmental pathways in glioma, pointing towards novel therapeutic targets including the HOXA signalling axis.
A biomechanical well plate inspired by the pressure-sensing lateral line of fish can wirelessly monitor the pulse of multiple lab-grown cardiac organoids simultaneously, offering a scalable new platform for cardiovascular drug testing.
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.